Evofem Biosciences (NASDAQ:EVFM – Get Free Report) and AEON Biopharma (NASDAQ:AEON – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.
Earnings & Valuation
This table compares Evofem Biosciences and AEON Biopharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evofem Biosciences | $11.39 million | 0.09 | $52.98 million | ($0.07) | -0.11 |
| AEON Biopharma | N/A | N/A | -$36.63 million | ($5.00) | -0.16 |
Risk & Volatility
Evofem Biosciences has a beta of -1.32, indicating that its share price is 232% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
Profitability
This table compares Evofem Biosciences and AEON Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evofem Biosciences | -46.42% | -91.97% | -61.93% |
| AEON Biopharma | N/A | N/A | -994.63% |
Insider and Institutional Ownership
0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Evofem Biosciences and AEON Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evofem Biosciences | 0 | 0 | 0 | 0 | 0.00 |
| AEON Biopharma | 0 | 1 | 1 | 1 | 3.00 |
Summary
AEON Biopharma beats Evofem Biosciences on 9 of the 13 factors compared between the two stocks.
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
About AEON Biopharma
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
